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Progressive encephalopathy in children with chronic renal insufficiency
in infancy. A retrospective analysis of children with renal failure during
the first year of life revealed that 20 of 23 patients developed profound
neurologic abnormalities. The encephalopathy was characterized by
developmental delay, microcephaly, hypotonia, seizures, dyskinesia,
and EEG abnormalities. No patient had been dialyzed, and four had not
received aluminum salts prior to the development of neurologic symp-
toms. Inadequate statural growth and poor nutrition were present in all
patients. It is probable that infants with chronic renal insufficiency are
more susceptible to the development of this syndrome than are older
children or adults because of the significant growth and maturation of
the brain that occurs during the first years of life.
Encephalopathie progressive chez des enfants atteints d'insuffisance
rénale chronique au cours de Ia petite enfance. Une analyse retrospective
rCalisée chez des enfants ayant eu une insuffisance rénale au cours de Ia
premiCre année de leur vie a montré que 20 sur les 23 malades étudiCs
ont développé des anomalies neurologiques importantes. L'encephalo-
pathie est caractCrisée par un retard de développement, une microcé-
phalie, une hypotonie, des crises convulsives, une dyskynésie, des
anomalies electroencephalographiques. Aucun de ces malades n'avait
ete en dialyse et 4 d'entre eux n'avaient pas recu de sels d'aluminium
avant l'apparition des signes neurologiques. Une croissance staturale
insuffisante et un mauvais état nutritionnel ont été constatés chez tous
les malades. II est probable que les enfants atteints d'insuffisance rénale
chronique sont plus exposés au developpement de ce syndrome que des
enfants plus âgés ou des adultes en raison de Ia croissance et de la
maturation importantes qui affectent le cerveau au cours des premieres
annCes de Ia vie.
The association of central nervous system disease (CNS) and
abnormal renal function was first noted over 30 years ago [1].
Acute brain syndromes with seizures and coma were common
neurologic complications of acute uremia, whereas peripheral
neuropathy and uremic encephalopathy were observed in slow-
ly progressive uremia ending with death [2—8]. With the advent
of dialysis and renal transplantation, this picture has changed.
In 1972, Alfrey et al [9] first recognized a progressive and
fatal encephalopathy in patients undergoing chronic hemodialy-
sis. This syndrome characterized by speech disturbance, de-
mentia, myoclonus, asterixis, and convulsions has been report-
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ed by others [10—53] but is poorly understood. In 1977, Baluarte
et al [54] reported a similar clinical picture in five uremic
children, none of whom were on dialysis. Six additional chil-
dren have been reported in 1980 [55—57].
This study describes our experience with 23 children who
developed chronic renal insufficiency before 1 year of age.
Twenty of these patients have developed progressive CNS
dysfunction unassociated with dialysis.
Methods
Charts of children with a diagnosis of chronic renal insuffi-
ciency (CR1) established prior to 1 year of age were reviewed.
Attempts were made to include all infants with CR1 seen at the
University of Minnesota Hospitals during the period 1968 to
1980, but because the analysis was retrospective, some pa-
tients, especially those with less severe disease, may have been
overlooked. Patients were identified by reviewing hospital
records with a discharge diagnosis of renal failure or renal
insufficiency, as well as records from the Divisions of Pediatric
Nephrology, Urology, and Transplant Surgery for this period.
For the purposes of this review, hypotonia was judged to be
present in patients when the neurological exam revealed a
decreased resistance to passive movement. Development was
assessed using the Denver Developmental Screen and either the
Bayley Scales of Infant Development or the Stanford-Binet
Intelligence Scale. A symptom or sign was considered to be
present from the time it was first documented in the patient's
chart.
Results
Twenty-three patients with CR1 in the first year of life were
identified on the basis of persistent elevation of serum creati-
nine. In 20 of the 23 patients, profound CNS dysfunction
developed.
Typically, a patient was noted to have CR!, then decreased
head growth, followed by seizures, dyskinesia, hypotonia, and
developmental delay. Clinical data for these 20 patients (17
males, 3 females) are given in Table 1. Patient 19 presented at 13
months of age but by history had antecedent renal insufficiency.
Initial values for serum creatinine are not available in two
patients, but subsequent determinations of creatinine were
elevated. In the remaining patients, the initial creatinine ranged
from 1.1 to 7.6 mg/dl. Renal dysplasia or hypoplasia with or
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Table 1. Age, sex, renal disease, and general outcome in patients with renal insufficiency and abnormalities of the central nervous system
Diagnosis of renal
insufficiency
— Age at last
Serum evaluation
Age creatinine or death
Patient Sex months mgldl Renal diseasea months Outcom&'
1 M At birth 3.2 Dysplasia, obstructive uropathy 88 Alive
transplanted (84)2 F 2 3.4 Dysplasia 20 Alive
3 M At birth 3.5 Dysplasia, obstructive uropathy,
posterior urethral valves
96 Alive
4 M At birth 1.3 Hypoplasia, obstructive
uropathy, posterior urethral
valves
126 Alive
5 M 11 2.8 Dysplasia, obstructive uropathy,
posterior urethral valves
47 Alive
transplanted (45)6 M At birth 2.3 Cystic-dysplasia, obstructive
uropathy
7 Dead
7 M 2 2.8 Dysplasia, obstructive uropathy,
posterior urethral valves
13 Dead
transplanted (12.5)8 M At birth 7.6 Hypoplasia, obstructive
uropathy
4.5 Dead
transplanted (1.5)9 F At birth 5.6 Dysplasia, ectopic ureteral
orifices
21 Dead
10 M 2 5.9 Dysplasia, obstructive uropathy 15 Dead
11 M 5 2.1 Dysplasia, obstructive uropathy,
posterior urethral valves
48 Dead
12 M 12 35c Obstructive uropathy, posterior
urethral valves
182 Alive
transplanted (160)
13 M At birth 2.1 Agenesis left kidney, right dys-
plasia, obstructive uropathy
64 Alive
14 F At birth 1.1 Dysplasia (Jeune's syndrome) 42 Dead
15 M 3 1.2 Agenesis left kidney, obstructive
uropathy and reflux on right
48 Alive
16 M 3 3.9 Polycystic kidneys 36 Alive
transplanted (22)
17 M At birth 6.5 Dysplasia, obstructive uropathy,
posterior urethral valves
27 Alive
18 M At birth 79 Cystic-dysplasia (Eagle-Barret),
posterior urethral valves
26 Dead
19 M 13 1.9 Medullary cystic disease 18 Dead
20 M At birth 4.5 Dysplasia 72 Dead
transplanted (40)
a The diagnosis was established by morphologic study of renal tissue at the time of biopsy or autopsy except in patients 12 and IS.b The number in parentheses indicates the age in months at which the kidney transplant was done.
Initial BUN where creatinine was not measured.
without associated obstruction was the most frequent diagnosis
leading to CR1.
Table 2 summarizes the neurologic data for each patient. In 3
patients, the presentation of CNS symptoms and CR1 was
simultaneous. In all other patients, the diagnosis of CR! preced-
ed recognition of any CNS dysfunction. There was no history of
difficult delivery or birth asphyxia, and there were no identifi-
able syndromes including neurologic dysfunction. The encepha-
lopathy was generally progressive and included one or more of
the following findings: developmental delay in 19 (95%), hypo-
tonia in 13 (65%), seizures in 13 (65%), and dyskinesia in 11
(55%). The occipital-frontal circumference (OFC) of the head
was below 2 SD for age in 15 patients and below 3 SD in 12 (Fig.
1).
Electroencephalograms (EEG) were abnormal in 17 of 18
patients evaluated. Eight patients had only a single EEG. The
first EEG was obtained before 1 year of age in 5 patients and
after the 5th birthday in 5 other patients. In 8 patients with
more than two EEG's, there was evidence of deterioration from
a normal record or one with modest slowing to an EEG
characterized by frequent bursts of generalized delta activity
with or without spikes. In this retrospective study, EEG's were
not obtained in some patients until clinical seizures or myo-
clonus were noted. Computerized axial tomography of the head
in 12 patients showed no abnormality in 5, cerebral cortical
atrophy in 5, and ventricular enlargement in 2. The cerebral
spinal fluid and electromyograms were normal in the five
patients where these were examined.
A marked reduction in height and growth velocity was
present in all patients. Based on the available data, patients
appear to have had normal head size at birth, but serial OFC
measurements fell below the normal range in 15 of 20 patients
(Figs. 2 and 3).
Serum calcium and phosphorus were measured in all pa-
tients, and the values varied widely during the patient's course
with no apparent relationship to the development of CNS
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Table 2. Age, duration of renal disease, and serum creatinine at recognition of central nervous system (CNS) abnormality in patients with renal
insufficiency
At recognition of CNS
manifestations
Recent
head
CNS abnormalityaDuration
of renal Serum
insufficiency creatinine Developmental
Patient months mg/d/ size delay Seizures Hypotonia Other EEGa, b CAT scana. b
1 83 5.0 <—1 SD + (83) + (83) — Tremor,
myoclonus (84)
Abnormal (84) Moderate
cortical
atrophy (84)
2 8 3.4 <—4 SD + (15) + (20) + (10) Tremor,
weakness,
truncal
instability (10)
Normal (7)
Abnormal (20)
ND
3 68 6.9 <—4 SD + (84) + (68) — Ataxia (68) Abnormal (68) ND
4 7 3.6 <—5 SD + (7) + (14) + (7) Ataxia (14) Abnormal (108) Normal (108)
5 0 1.8 <—1 SD + (28) + (11) — — Normal (33)
Abnormal (36)
ND
6 4 2.5 <—3 SD + (4) + (4) + (4) Chorea,
weakness,
myoclonus (4)
Abnormal (7) Mild
cortical
atrophy (7)
7 0 2.8 <—1 SD + (2) — — Abnormal (2) Normal (2)
8 0.5 3.7 <—3 si + (0.5) + (0.5) + (0.5) — Abnormal (4) Mild
ventricular
enlargement (3)
9 2 5.6 <—3 SD + (11) — + (11) Chorea (2) Abnormal (16) Cortical
atrophy (5)
10 11 5.0 <—3 SD + (13) — — Chorea (13) ND ND
11 0 2.1 <—2 SD + (36) + (5) — Decreased
alertness (36)
Abnormal (5) Normal (36)
12 156 3.0 <—2 SD + (168) + (168) + (168) Ataxia,
chorea,
myoclonus (168)
Abnormal (178) Normal (180)
13 60 1.8 <—4 SD + (60) — — Upper motor
neuron
deficit (60)
Abnormal (63) ND
14 36 1.1 >+l SD + (36) + (36) + (36) Subdural
effusion (36)
Abnormal (36) Moderate
ventricular
enlargement (36)
15 27 1.4 Mean + (30) + (30) + (30) Dysarthria,
dementia,
lethargy (30)
Normal (30)
Abnormal (44)
Normal (30)
16 15 3.6 <—3 SD + (22) + (18) + (18) Chorea,
athetosis (27)
Abnormal (18) Cortical
atrophy (18)
17 18 6.5 <—6 SD + (18) — + (18) — Abnormal (27) Cortical
atrophy (27)
18 14 3.8 <—3 SD + (14) — + (14) — Abnormal (16) ND
19 2 2.9 <—2 SD + (18) — + (18) Lethargy (15) Normal (17) ND
20 38 5.0 <—3 SD + (38) — + (38) Tremor, wide
based gait (38)
ND ND
a The number in parenthesis indicates the age in months at which observation was first made.
b ND = not done.
disease. Parathyroid hormone (PTH) was normal in 4 patients
(3, 14, 15, and 8) and elevated in 4 others (1, 12, 16, and 17). In
patient 3, the PTH was normal both 16 months before and at the
time of his presentation with seizures and ataxia.
Serum electrolytes were usually normal, although most pa-
tients had a low serum bicarbonate at presentation and required
oral alkali therapy. Patient 19 never received oral aluminum
hydroxide as an agent to reduce phosphate absorption; in 3
other patients (5, 7, 11) oral aluminum therapy was initiated
only after the recognition of CNS disease.
The prescribed diet for patients with CR! includes an ade-
quate amount of high biologic value protein and calories,
contains low phosphorus and potassium, and provides appro-
priate amounts of sodium and water. In addition, vitamin D,
diuretics (furosemide or thiazide), iron, folic acid, multiple
vitamins, and sodium polystyrene resin were prescribed as
required.
Seven patients have received kidney transplants, all were
treated with antilymphocyte globulin, azathioprine, and predni-
sone. Patients 7 and 8 died at 0.5 and 3 months after transplanta-
tion with graft rejection. Patient 20 was transplanted successful-
ly but succumbed to varicella 32 months after transplantation.
The 4 remaining patients have functioning renal transplants.
Patient 12 showed improvement in his dyskinesia and reduced
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Fig. 3. Serialmeasurements of head circumference in 20 patients with
renal insufficiency and central nervous system (CNS) abnormalities.
The stippled area defines the mean 2 SD for boys (adapted from Ref.
77). Numbers refer to patient numbers in Tables I and 2.
had an elevated creatinine (1.1 to 2.7 mg/dl) since 11 months of
age. Although his OFC is 2 SD below the mean, he has had no
evidence of other CNS disease and is currently in college. The
second patient is a 16-month-old boy who has been followed
since 3 months of age with a diagnosis of renal dysplasia
associated with posterior urethral valves. He has a normal OFC
and a serum creatinine of 2.9 mgldl. The third patient is a 5½-
year-old girl who has dysplastic kidneys and a serum creatinine
of 2.8 mg/dl. She has been observed for more than 5 years, has a
normal OFC, and has no evidence of CNS dysfunction. Of the 3
patients without CNS abnormalities, 2 have received oral
aluminum hydroxide for 13 and 54 months, respectively.
Discussion
Fig. 2. Serial measurements of height in the 20 patients with chronic
renal insufficiency and central nervous system (CNS) abnormalities.
The stippled area defines the 5th to the 95th percentile of normal for
boys (76). Numbers refer to patient case numbers in Tables 1 and 2. Age
at the time of renal transplant in 7 patients is indicated by an arrow.
frequency of seizures but still has significant developmental
delay. Inpatient 16, worsening of his CNS disease has occurred
with the appearance of seizures. In patients 4 and 5, followed
for 2 and 4 months, no significant change in CNS status was
apparent.
Of the 20 patients, 10 have died. Microscopic examination of
the brain in 5 patients failed to reveal consistent changes. In 4
patients (6, 7, 8, 9) the brain was weighed and was more than 2
SD below the mean for either age or height.
In marked contrast to the 20 patients with encephalopathy, 3
patients with CR1 in infancy have no evidence of CNS abnor-
mality. The first, a 19-year-old boy with dysplastic kidneys, has
A retrospective analysis of 23 children with CR! since infancy
revealed that 20 developed profound neurologic abnormalities.
This progressive encephalopathy was characterized by a
marked delay in attaining developmental milestones and the
appearance of seizures, dyskinesia, and hypotonia. All of these
symptoms were associated with the failure of normal head
growth. As in other reports [54—57], our patients are heterogen-
bus with respect to the degree of CR1 and the type of major
CNS abnormality noted. Because 8 of 17 patients had posterior
urethral valves, the disproportionate number of male patients
probably reflects the frequency with which obstructive uropa-
thy causes renal failure early in life.
In some respects the clinical findings and the EEG abnormali-
ties in these patients are similar to those described in adults
with dialysis dementia—a syndrome in which aluminum toxici-
ty has been implicated [9, 10, 18, 19, 21, 22, 24, 25, 27, 29—32,
34—41, 43—46, 48, 50, 54, 56, 58]. In those patients, the
aluminum comes from two sources: dialysis water and oral
aluminum-based phosphate-binding agents. None of our pa-
tients was dialyzed prior to the appearance of CNS dysfiinction,
an experience shared by others. In addition, 4 patients devel-
oped CNS symptoms before receiving any oral aluminum
therapy and in this way differ from earlier reports [54, 56, 57].
So despite similarities, the encephalopathy in these children
Fig. 1. Diagram showing the incidence of each of the five major findings
in 20 patients with progressive encephalopathy. The diagram also
indicates the percentage association of each individual finding with the
other 4.
Age
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with CR1 may have a different pathogenesis from the dementia
seen in adult dialysis patients.
Growth failure in children with uremia is not explained easily,
and no single cause has been identified [61—65]. Because of the
complexities involved, it is not surprising that multiple explana-
tions have been considered including: toxins, poor dietary
intake, abnormal intermediary metabolism, vitamin D deficien
cy, acidosis, hyperparathyroidism, and so on. The relationship
of statural growth failure to the neurologic abnormalities ob-
served is obscure, but no patient in the current series developed
neurologic symptoms in the absence of significant growth
retardation, and in most patients the latter was evident first.
Although it has long been recognized that young children with
CR! do not grow normally, it is curious that it has taken so long
to recognize this association with progressive CNS disease.
This may be related to the mistaken notion that the CNS
abnormalities were associated with a genetic defect, Now better
dialysis and transplantation for small children have increased
their survival and permitted recognition of this syndrome.
Inadequate nutrition may be important in the evolution of this
syndrome. Our patients were sick, underwent surgery, were
hospitalized for several months in the first years of life, and
undoubtedly had suboptimal caloric intake. Experimental ani-
mal studies [66—71] and clinical studies in man [68, 72—75]
suggest that a critical period of brain growth may exist. In
children this may extend into the second year of life, and during
that time even mild or short term malnutrition may produce
irreversible damage. Reduced IQ, speech disorders, and EEG
abnormalities have been reported in studies of human and
animal malnutrition [68, 76]. No one, however, has reported
CNS dysfunction as severe as that seen in our patients on the
basis of malnutrition alone.
Parathyroid hormone has been suggested as a potential
neurotoxin [59, 60] responsible for some of the neurologic
abnormalities observed in uremia. Unfortunately, only random
determinations of PTH were available for 8 of our patients, and
4 of these were normal. Of interest, the level of PTH was
normal in 1 patient, both 16 months before and at the time of his
presentation with CNS symptoms.
A variety of other causes had been suggested for the neuro-
logic abnormalities recognized in uremia. At present none of
these hypotheses has been proven, however, the high incidence
of encephalopathy in these patients may reflect a unique
vulnerability of the immature brain to the uremic environment.
Because this study is retrospective, there is incomplete data on
the pathogenetic role of nutrition, PTH, aluminum, or other
variables.
That 3 children with CR1 are neurologically intact but are
otherwise indistinguishable from the 20 affected patients sug-
gests the existence of other unrecognized determinant(s) of this
syndrome. In view of this, it is not clear what therapeutic tactic
should be used to protect the developing brain or alter the
progression of the encephalopathy. The usual dietary therapy
attempts to regulate calcium-phosphorus metabolism and con-
trol of acidosis, and was used in all these patients. Although it is
possible that a more rigorous application of these therapeutic
principles may be beneficial, the appearance of new symptoms
during therapy in some of these patients suggests that a more
direct approach is required. Earlier renal transplantation may
be necessary to protect or stabilize the developing brain, and
we are presently pursuing this strategy.
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